KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) EBITDA Margin: 2017-2025

Historic EBITDA Margin for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to -120.61%.

  • Aquestive Therapeutics' EBITDA Margin fell 3562.00% to -120.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 524.32%, marking a year-over-year increase of 58407.00%. This contributed to the annual value of -4,378.67% for FY2024, which is 436311.00% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' EBITDA Margin is -120.61%, which was up 10.95% from -135.44% recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' EBITDA Margin registered a high of 72.46% during Q1 2023, and its lowest value of -618.35% during Q2 2021.
  • Over the past 3 years, Aquestive Therapeutics' median EBITDA Margin value was -61.42% (recorded in 2023), while the average stood at -66.75%.
  • As far as peak fluctuations go, Aquestive Therapeutics' EBITDA Margin spiked by 41,458bps in 2022, and later plummeted by 17,889bps in 2024.
  • Aquestive Therapeutics' EBITDA Margin (Quarterly) stood at -261.28% in 2021, then surged by 14,565bps to -115.63% in 2022, then skyrocketed by 5,421bps to -61.42% in 2023, then soared by 9,959bps to 38.17% in 2024, then tumbled by 3,562bps to -120.61% in 2025.
  • Its EBITDA Margin stands at -120.61% for Q3 2025, versus -135.44% for Q2 2025 and -262.96% for Q1 2025.